+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptic Ulcer Drugs Market by Route Of Administration (Oral, Parenteral), Sales Channel (Over The Counter, Prescription Drugs), Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast 2025-2030- Product Image
Peptic Ulcer Drugs Market by Route Of Administration (Oral, Parenteral), Sales Channel (Over The Counter, Prescription Drugs), Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast 2025-2030- Product Image
Sale

Peptic Ulcer Drugs Market by Route Of Administration (Oral, Parenteral), Sales Channel (Over The Counter, Prescription Drugs), Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889038
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptic Ulcer Drugs Market grew from USD 4.73 billion in 2024 to USD 4.99 billion in 2025. It is expected to continue growing at a CAGR of 5.25%, reaching USD 6.43 billion by 2030.

A Comprehensive Overview of the Peptic Ulcer Therapeutics Landscape That Frames Current Treatment Paradigms Clinical Challenges and Emerging Innovations

Peptic ulcer disease remains a pressing gastrointestinal health challenge, driven by Helicobacter pylori infection, chronic use of nonsteroidal anti-inflammatory drugs and evolving patient demographics. Recent scientific breakthroughs have deepened our understanding of mucosal defense mechanisms and gastric acid regulation, leading to the development of more targeted therapies.

Against this backdrop, stakeholders face a complex environment shaped by regulatory reforms, changing reimbursement policies and heightened scrutiny of drug safety profiles. The introduction of novel proton pump inhibitors alongside established H2 receptor antagonists continues to redefine clinical practice guidelines and patient care pathways. Consequently, manufacturers and healthcare providers must adapt to shifting treatment protocols, payer expectations and patient adherence dynamics.

Transitioning from traditional empirical therapy toward personalized medicine approaches, the peptic ulcer space now emphasizes risk stratification, pharmacogenomics and integrated patient management. As we begin this executive summary, our aim is to frame the critical factors informing therapeutic strategy, supply chain resilience and stakeholder decision-making in this rapidly evolving market.

Analyzing the Impact of Technological Disruptions Shifting Patient Centric Innovations and Regulatory Changes Reshaping Peptic Ulcer Drug Development

The peptic ulcer treatment paradigm has undergone transformative shifts driven by digital health adoption, telemedicine proliferation and precision diagnostics. Wearable pH monitoring devices and remote patient engagement platforms enable real-time assessment of acid suppression efficacy, improving treatment compliance and clinical outcomes.

Simultaneously, regulatory authorities are streamlining approval pathways for first-in-class molecules while enhancing post-market surveillance requirements. This dual trend accelerates innovation but elevates the bar for demonstrating safety and long-term efficacy. Moreover, strategic alliances between pharmaceutical companies and technology vendors are driving the integration of data analytics into drug development, refining patient selection criteria and optimizing dosing regimens.

Furthermore, the rise of patient-centric care models has shifted the emphasis from acute symptom management to comprehensive ulcer prevention strategies, incorporating lifestyle interventions, microbiome modulation and eradication protocols. As a result, industry players are realigning R&D investment priorities toward combination therapies and next-generation inhibitors that address unmet clinical needs while delivering differentiated value propositions.

Assessing the Cumulative Effects of 2025 United States Tariff Measures on Peptic Ulcer Drug Supply Chains Clinical Pricing and International Trade Dynamics

Beginning in early 2025, the United States implemented a series of tariff measures affecting pharmaceutical imports, including active pharmaceutical ingredients and finished dosage forms used in peptic ulcer therapies. These duties have introduced new pressures on supply chain cost structures, compelling manufacturers to reassess sourcing strategies and contract manufacturing partnerships in low-cost geographies.

In response, many stakeholders have accelerated nearshoring efforts and diversified supplier portfolios to mitigate exposure to tariff-induced price fluctuations. Concurrently, wholesalers and distributors are renegotiating agreements to preserve margin stability, while pharmacy systems are evaluating inventory management protocols to avoid stockouts and ensure continuous patient access.

As tariffs persist, the interplay between import duties, currency volatility and inbound freight rates will remain a critical consideration for strategic procurement teams. Ultimately, the cumulative impact of these measures extends beyond cost alone, influencing product launch timelines, pricing negotiations with payers and cross-border collaboration models among multinational pharmaceutical corporations.

Analyzing Segment Level Insights by Administration Sales Channels Brand Type Dosage Form End User Distribution and Drug Class in Peptic Ulcer Treatment

A granular review of market segments reveals distinct dynamics by route of administration, with oral therapies retaining broad patient acceptance due to convenience while parenteral formulations are increasingly utilized in acute hospital settings for rapid symptom control. Sales channels continue to evolve as over-the-counter access expands patient self-management, even as prescription channels remain indispensable for specialized compounds requiring physician oversight.

Branded products maintain premium positioning through investment in novel mechanism-of-action claims, whereas generics drive cost-containment efforts and enable broader patient reach. Dosage form preferences vary globally: capsules and tablets dominate outpatient regimens, while injections are concentrated in institutional care environments. End user patterns highlight the growing importance of home care models for long-term maintenance therapy, contrasted with hospitals and outpatient clinics for initial ulcer management.

Distribution routes reflect the digital transformation of pharmacies, integrating online ordering platforms alongside traditional hospital and retail pharmacies to enhance patient convenience. Within drug classes, H2 receptor antagonists such as cimetidine, famotidine, nizatidine and ranitidine continue to serve as first-line options for moderate ulcer cases, while proton pump inhibitors including esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole dominate advanced therapy protocols due to superior acid suppression and healing rates.

Revealing Critical Patterns and Strategic Divergences Across the Americas Europe Middle East Africa and Asia Pacific in Peptic Ulcer Drug Provisioning

Regional performance in the Americas underscores robust uptake of proton pump inhibitors driven by established healthcare infrastructures and favorable reimbursement frameworks. Canada’s formulary adjustments and U.S. payer negotiations are shaping formulary placements, while Latin American markets demonstrate resilience as local generic manufacturers scale production to meet rising treatment demand.

In Europe, Middle East and Africa, regulatory harmonization efforts under the European Medicines Agency and emerging markets’ drive for healthcare access are fostering parallel import strategies and adaptive pricing models. The Gulf Cooperation Council’s procurement alliances and sub-Saharan Africa’s public health initiatives are amplifying outreach programs, albeit within constrained budget envelopes.

The Asia-Pacific region presents a multifaceted picture, with Japan and Australia leading in innovation adoption and real-world evidence generation. Southeast Asian nations are navigating regulatory complexity to attract contract manufacturing investment, while India and China continue to expand capacity for both active ingredients and finished dosage forms. Across all territories, shifting demographic profiles and evolving payer expectations are key drivers in shaping regional strategic agendas.

Unveiling Strategic Moves by Key Industry Players in R&D Alliances Portfolio Diversification Digital Integration and Manufacturing Expansion

Leading pharmaceutical companies are intensifying their focus on pipeline diversification, balancing mature H2 receptor antagonist franchises with next-generation proton pump inhibitors that promise enhanced safety profiles and targeted delivery mechanisms. Major innovators are investing in gastroretentive formulations and nanotechnology-enabled platforms to improve drug solubility and patient adherence.

Smaller biotech firms are forging strategic partnerships to access commercialization expertise, while contract development and manufacturing organizations are expanding their service portfolios to include sterile parenteral and orphan drug production capabilities. Meanwhile, specialty generics manufacturers are consolidating through acquisitions to achieve scale economies and streamline regulatory compliance across multiple jurisdictions.

Additionally, cross-sector alliances between pharmaceutical entities and digital health companies are producing integrated solutions that combine pharmacotherapy with remote monitoring, leading to more holistic treatment paradigms. Intellectual property landscapes are evolving as key patents expire and exclusivity windows shorten, prompting competitive repositioning and value-based contracting discussions.

Implementing Precision Medicine Investments Adaptive Supply Chain Strategies Digital Adherence Solutions and Cross Industry Collaborations to Drive Sustainable Growth

Industry leaders should accelerate investment in precision acid suppression therapies that leverage pharmacogenomic profiling to optimize clinical outcomes. By establishing real-world evidence partnerships with healthcare systems, organizations can demonstrate differential efficacy and safety, strengthening positioning in value-based reimbursement negotiations.

To mitigate tariff-related supply disruptions, procurement teams must develop multi-sourcing frameworks and collaborative risk-sharing contracts with strategic suppliers. Furthermore, integrating advanced analytics into demand forecasting will enhance inventory resilience, ensuring continuity of care across all treatment settings.

Stakeholders should also explore digital adherence solutions, combining mobile health applications with teleconsultation services to reinforce long-term maintenance regimens. Finally, fostering cross-industry innovation through incubators or venture collaborations will help identify breakthrough therapies and delivery platforms, sustaining competitive advantage in the evolving peptic ulcer market.

Detailing a Comprehensive Research Framework Combining Regulatory Analysis Primary Stakeholder Interviews Trade Flow Modeling Prescription Audit and Regional Expert Consultations

Our research methodology integrates a multi-layered approach combining primary and secondary data sources. Regulatory filings, patent databases and clinical trial registries were meticulously reviewed to map therapeutic pipelines and exclusivity landscapes. In parallel, proprietary interviews with key opinion leaders, procurement directors and manufacturing executives provided firsthand insights into emerging trends and operational challenges.

Extensive analysis of customs documentation, tariff schedules and trade flow statistics underpinned the evaluation of the United States’ 2025 tariff impacts. We applied supply chain risk modeling techniques to simulate cost and lead time sensitivities across varying duty scenarios. Segmentation analysis drew upon prescription audit data, retailer panel surveys and wholesaler shipment records to capture distribution nuances by channel and dosage form.

Regional market dynamics were validated through consultation with local market experts and public health agencies, ensuring a robust understanding of reimbursement frameworks and policy drivers. All qualitative findings were triangulated with quantitative metrics to ensure rigorous, actionable insights suitable for strategic decision-making.

Synthesizing Therapeutic Innovations Trade Policy Impacts Segmentation and Regional Dynamics to Guide Strategic Prioritization

In summary, the peptic ulcer drugs landscape is at an inflection point defined by emerging therapeutic innovations, shifting trade policies and evolving patient care paradigms. The integration of precision medicine approaches, advanced formulation technologies and digital health solutions promises to elevate treatment outcomes, while tariff pressures and demographic shifts necessitate adaptive supply chain strategies.

Segmentation and regional analyses reveal that stakeholder success will hinge on the ability to tailor offerings across diverse channels, geographies and patient populations. Key companies are responding with portfolio optimizations, strategic alliances and manufacturing expansions aimed at sustaining growth in a competitive environment.

Ultimately, decision-makers must balance near-term operational resilience with long-term innovation investments to navigate this dynamic market effectively. By leveraging the insights and recommendations presented herein, industry leaders can chart a path toward enhanced clinical value, cost efficiency and strategic differentiation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Oral
    • Parenteral
  • Sales Channel
    • Over The Counter
    • Prescription Drugs
  • Brand Type
    • Branded
    • Generic
  • Dosage Form
    • Capsule
    • Injection
    • Tablet
  • End User
    • Home Care
    • Hospitals
    • Outpatient Clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Drug Class
    • H2 Receptor Antagonists
      • Cimetidine
      • Famotidine
      • Nizatidine
      • Ranitidine
    • Proton Pump Inhibitors
      • Esomeprazole
      • Lansoprazole
      • Omeprazole
      • Pantoprazole
      • Rabeprazole
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Bayer AG
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing antibiotic resistance in H. pylori strains driving demand for novel eradication therapies
5.2. Growing uptake of generic proton pump inhibitors leading to intensified price competition in developed markets
5.3. Development of sustained-release drug delivery systems to enhance peptic ulcer treatment adherence
5.4. Rising investment in cytoprotective peptide analogues as next generation ulcer healing agents
5.5. Expansion of personalized therapy strategies based on patient genetic profiling and microbial genomics
5.6. Surge in natural and plant-derived antiulcer compounds spurred by consumer preference for herbal remedies
5.7. Regulatory advisories on long-term PPI use reshaping prescribing practices and patient management guidelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peptic Ulcer Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Peptic Ulcer Drugs Market, by Sales Channel
9.1. Introduction
9.2. Over The Counter
9.3. Prescription Drugs
10. Peptic Ulcer Drugs Market, by Brand Type
10.1. Introduction
10.2. Branded
10.3. Generic
11. Peptic Ulcer Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Injection
11.4. Tablet
12. Peptic Ulcer Drugs Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospitals
12.4. Outpatient Clinics
13. Peptic Ulcer Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Peptic Ulcer Drugs Market, by Drug Class
14.1. Introduction
14.2. H2 Receptor Antagonists
14.2.1. Cimetidine
14.2.2. Famotidine
14.2.3. Nizatidine
14.2.4. Ranitidine
14.3. Proton Pump Inhibitors
14.3.1. Esomeprazole
14.3.2. Lansoprazole
14.3.3. Omeprazole
14.3.4. Pantoprazole
14.3.5. Rabeprazole
15. Americas Peptic Ulcer Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Peptic Ulcer Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Peptic Ulcer Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AstraZeneca plc
18.3.2. Takeda Pharmaceutical Company Limited
18.3.3. Eisai Co., Ltd.
18.3.4. Pfizer Inc.
18.3.5. Johnson & Johnson
18.3.6. Sanofi S.A.
18.3.7. GlaxoSmithKline plc
18.3.8. Bayer AG
18.3.9. Novartis AG
18.3.10. Teva Pharmaceutical Industries Ltd
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. PEPTIC ULCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. PEPTIC ULCER DRUGS MARKET: RESEARCHAI
FIGURE 30. PEPTIC ULCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. PEPTIC ULCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. PEPTIC ULCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PEPTIC ULCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 126. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 127. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 134. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 135. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 144. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 145. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 234. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 235. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 236. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 237. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 252. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 253. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 254. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 255. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 288. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 289. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 290. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 291. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 296. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 297. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 298. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 299. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 306. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 307. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 308. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 309. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 314. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 315. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 318. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS,

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Peptic Ulcer Drugs market report include:
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Bayer AG
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.99 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.43 Billion
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Peptic Ulcer Drugs - Global Strategic Business Report - Product Image

Peptic Ulcer Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Peptic Ulcer Drugs Market by Product Type, Ulcer Type, Distribution Channel, and Region 2025-2033 - Product Image

Peptic Ulcer Drugs Market by Product Type, Ulcer Type, Distribution Channel, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
Peptic Ulcer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Peptic Ulcer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 215 Pages
  • Global
From
Peptic Ulcers Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Peptic Ulcers Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 150 Pages
  • Global
From

About the Peptic Ulcer Drug Market

The Peptic Ulcer Drug market is a subset of the Gastrointestinal Drugs market, which includes medications used to treat diseases and disorders of the digestive system. Peptic Ulcer Drugs are used to treat peptic ulcers, which are sores that form in the lining of the stomach or small intestine. These drugs work by reducing the amount of acid produced in the stomach, which helps to reduce pain and promote healing. Commonly used Peptic Ulcer Drugs include proton pump inhibitors, H2 blockers, and antacids. The Peptic Ulcer Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, AstraZeneca, Merck, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.